King Luther Capital Management Corp Sells 34,470 Shares of Thermo Fisher Scientific Inc. $TMO

King Luther Capital Management Corp lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 733,963 shares of the medical research company’s stock after selling 34,470 shares during the period. Thermo Fisher Scientific comprises about 1.3% of King Luther Capital Management Corp’s portfolio, making the stock its 18th largest position. King Luther Capital Management Corp’s holdings in Thermo Fisher Scientific were worth $297,593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. CBIZ Investment Advisory Services LLC increased its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific in the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. grew its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a research note on Tuesday, October 28th. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company upped their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Stock Up 1.2%

Shares of NYSE:TMO opened at $572.72 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock’s 50-day moving average price is $518.58 and its 200-day moving average price is $462.59. The stock has a market capitalization of $215.18 billion, a P/E ratio of 33.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific declared that its board has authorized a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,420 shares of company stock worth $19,980,884 in the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.